- Aucune donnée
Français
- English
- 简体中文
- 繁体中文
- Français
- Русский
- Italiano
- 日本語
- 한국어
- Português
- Deutsch
- Español
- Türkçe
- Ελληνικά
- Nederlands
- Tiếng Việt
- Polski
Recently, Professor Zhang Xiaohong and Professor Peng Jun from the Functional Nanomaterials and Soft Materials Research Institute (FUNSOM) of Suzhou University, along with Professor Mohammad Khaja Nazeeruddin, Professor Paul J. Dyson, Professor Zhaofu Fei, and Professor Ding Yong from North China Electric Power University, collaborated to publish their research findings on Dopant additive synergy ...
Recently, Zhang Weijun, a research team of the Anguang Institute of the Chinese Academy of Sciences, Hefei Academy of Materials, made new progress in atmospheric formaldehyde detection, and the related achievements were published on the international TOP journal Sensors and Actors: B. Chemical under the title of "Portable highly sensitive laser absorption spectrum formaldehyde sensor based on comp...
Semi light, partially matter quasi particles, known as excitons polaritons, can easily bypass obstacles and condense into a single coherent state - both of which are characteristics of topological insulators. Researchers from the United States and China have developed a new technology to manufacture microcavities from chloride based halide perovskites. They expect this work to lead to a new type o...
In April 2024, GE Additive was renamed Colibrium Additive. Colibrium Additive (formerly GE Additive) is a subsidiary of GE Aerospace Propulsion and Additive Technology (PAT) and was established at the end of 2016. Nowadays, it is a trusted partner and manufacturer of industrial metal 3D printers and metal powders, as well as a service provider for industrial metal 3D printers and metal powders. It...
On July 3rd local time, Swiss ophthalmic care giant Alcon announced the acquisition of Israeli medical technology company Belkin Vision and its laser equipment assets for treating glaucoma.The transaction includes a prepayment of $81 million, of which approximately $65 million is in cash. In addition, if Alcon can establish this technology as the preferred first-line treatment option for clinical ...